Q4 Systemwide Pro Forma Revenue increased to $25.0 million , with full year 2020 Systemwide Pro Forma sales of $88.1 million

Q4 Adjusted EBITDA increased 59% sequentially to $5.9 million , representing Adjusted EBITDA margin of 24%


Reiterated FY2021 guidance for Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million

The Company’s existing licensed projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million , respectively

PHOENIX , April 6, 2021 /CNW/ – 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2020 . All financial information is presented in U.S. dollars unless otherwise indicated.

Fourth Quarter 2020 (“Q4 2020”) Financial Results Highlights

  • Systemwide Pro Forma Revenue was $25.0 million
  • GAAP-reported revenue was $17.0 million
  • Adjusted EBITDA was $5.9 million

Fiscal Year 2020 (“FY 2020”) Financial Results Highlights

  • Systemwide Pro Forma Revenue was $88.1 million
  • GAAP-reported revenue was $57.6 million , a 203% increase compared to the prior year
  • Adjusted EBITDA was $5.9 million

Operational Highlights

  • Opened second Illinois Mission Dispensary in Calumet City , and recently announced 2021 expansion plans in Illinois which includes the build out of an up to 558,000 square foot cultivation and production facility
  • Completed expansion and retrofit of cultivation and production facility in Georgetown, MA and Elk Grove Village, IL. Continued construction on state-of-the-art 185,000 square foot production facility in Commerce, California , fully funded and on track for Q2 2021 opening
  • Third Massachusetts dispensary in Brookline on track for Q2 2021 opening
  • Completed sale leaseback transaction with Innovative Industrial Properties; ended year with $18.9 million of cash and $47.3 million in long-term debt due in May 2024

Management Commentary

“4Front’s strong fiscal 2020 performance is validation that our core strategy of replicating low-cost production methods, developed and refined within our Washington facilities, combined with our steadfast focus on execution is working,” said Leo Gontmakher , Chief Executive Officer of 4Front. “We ended 2020 with tremendous business momentum that we have carried into the new year, as we scaled and replicated our operations across the growing adult-use markets of Massachusetts , Illinois and California .”

Mr. Gontmakher added, “Our strong performance was driven by growing consumer demand for our quality manufactured products introduced in Massachusetts over the last year, the continued strength of the Illinois market, and a solid quarter out of our Washington facilities. We also completed the construction of our second Illinois dispensary in Calumet City , which opened in December, plus our cultivation/manufacturing facilities in Illinois and Massachusetts which we successfully transitioned into the ‘Washington Way’ with cultivation yields now meeting or exceeding those from our Washington facilities.”

Mr. Gontmakher concluded, “We are well positioned to further scale the business and execute on our expansion strategy in 2021. This includes significantly expanding our cultivation and manufacturing footprint in Illinois and entering the $3 billion California market. Further bolstering our financial position is the fact that we are now generating positive operating cash flow, in line with our stated goals from the start of the year. Given the strength of our operations, I am pleased to reiterate our 2021 guidance of $170 $180 million in Pro Forma Systemwide Revenue and $40 $50 million in Adjusted EBITDA, with the longer-term view to generate $650 million in revenue and $250 million in EBITDA based on our current licensed footprint.”

Business Updates and Developments

Q4 2020 Systemwide Pro Forma Revenue increased 12% quarter-over-quarter to $25.0 million . This growth was driven by continued robust activity across the Company’s portfolio of operating assets, led by the first full quarter of recreational sales in Massachusetts and the opening of 4Front’s second Illinois retail location in Calumet City.

Q4 Adjusted EBITDA increased 59% quarter-over-quarter to $5.9 million representing adjusted EBITDA margin of 24%. The Company continued to demonstrate considerable operating leverage in the fourth quarter, exceeding internal expectations, after initially achieving profitability during the third quarter of 2020.  Through the combination of 4Front’s low-cost production model, tight expense controls, and accelerating revenues the Company is well positioned to extend its profitability as it scales up its operating footprint. The Company achieved positive operating cash flow of $3.2 million in Q4 2020 and remains poised to show significant operating leverage in 2021.

In Q4 2020 4Front opened its second Illinois Mission Dispensary in Calumet City , and recently announced additional 2021 expansion plans in Illinois . The expansion plan includes the build out of an up to 558,000 square foot cultivation and production facility (the “Facility”), which the Company recently secured financing to build. Subsequent to the year end, the Company entered into definitive agreements with both the landowner and an affiliate of Innovative Industrial Properties, Inc., to acquire the land for $6.5 million and fund the approximately $45 million buildout of phase one of the Facility. The first phase constitutes 258,000 square feet of building comprising 65,000 square feet of flowering canopy with approximately 70,000 square feet of manufacturing space and is expected to be operational in the fourth quarter of 2022.

The Company’s fully-funded, state-of-the-art 185,000 square foot manufacturing only facility in Commerce, California is nearing completion and is expected to be ready to serve the California cannabis market in Q2 2021. The Company is planning to launch its first full line of edibles, tinctures and vape products on California retail shelves starting in May 2021 .

Construction remains on schedule at the Company’s third Massachusetts dispensary in Brookline . Final inspection by the Cannabis Control Commission anticipated to occur in June 2021 and the Company remains confident that it will open the Brookline dispensary in Q2 2021.

2021 Outlook

Based on the continued strength of the Company’s operations and robust consumer demand, 4Front reiterates its previously announced FY 2021 guidance and anticipates Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million. This guidance is fully funded and contemplates only current operations plus the opening of the Brookline, Massachusetts dispensary and the Commerce production facility in Q2 of 2021. If such openings are delayed due to Covid-19, guidance could be negatively affected.

(Please see Note Regarding Non-GAAP Measures, Reconciliation, and Discussion below.) (*Please see the Financial Statement section below, and the Company’s Fourth Quarter 2020 Condensed Consolidated Financial Statements and Management Discussion and Analysis (“MD&A”), available under the Company’s EDGAR profile)

Additional Details

As of the date of the MD&A, there were the equivalent of 566,186,697 Class A Subordinate Voting Shares outstanding when calculated as if all share classes were converted to Subordinate Voting Shares. For further details regarding 4Front’s share structure, please see its profile at www.thecse.com .

Conference Call

The Company will also host a conference call and webcast on Tuesday, April 6, 2021 at 5:00 p.m. ET to review its operational and financial results and provide an update on current business trends.

To join the call, dial 1-877-407-0792 toll free from the United States or Canada or 1-201-689-8263 if dialing from outside those countries. The webcast can be accessed at this link .

The call will be available for replay until Tuesday April 13, 2021 . To access the telephone replay, dial 1-844-512-2921 toll free from the United States and Canada , or 1-412-317-6671 if dialing from outside those countries, and use this replay pin number: 13717894.

About 4Front Ventures Corp.

4Front (CSE: FFNT) (OTCQX: FFNTF) is a national multi-state cannabis operator and retailer, with a market advantage in mass-produced, low-cost quality branded cannabis products. 4Front manufactures and distributes a portfolio of over 25 cannabis brands including Marmas, Crystal Clear , Funky Monkey, Pebbles, and the Pure Ratios wellness collection, distributed through retail outlets and their chain of strategically positioned Mission branded dispensaries.

Headquartered in Phoenix, Arizona , 4Front has operations in Illinois , Massachusetts , California , Michigan , and Washington state . From plant genetics to the cannabis retail experience, 4Front’s team applies expertise across the entire cannabis value chain. For more information, visit 4Front’s website www.4frontventures.com .

Financial Statements

4Front Ventures Corp.
Formerly 4Front Holdings, LLC
Consolidated Balance Sheets
As of December 31, 2020 and December 31, 2019


December 31,

December 31,

Amounts expressed in thousands of U.S. dollars except for share and per share data

2020

2019

ASSETS

Current assets:

Cash

$

18,932

$

5,789

Accounts receivable

437

597

Other receivables

1,341

405

Current portion of lease receivables

3,450

9,556

Inventory

18,037

9,825

Current portion of notes receivable

264

1,871

Prepaid expenses

2,275

2,198

Total current assets

44,736

30,241

Restricted cash

2,352

Property and equipment, net

33,618

41,822

Notes receivable and accrued interest

91

1,049

Lease receivables

7,595

23,944

Intangible assets, net

28,790

35,147

Goodwill

23,155

40,283

Right-of-use assets

62,466

20,757

Investments

759

Deposits

4,305

6,347

TOTAL ASSETS

$

204,756

$

202,701

LIABILITIES AND SHAREHOLDERS’ EQUITY

LIABILITIES

Current liabilities:

Accounts payable

$

4,722

$

5,866

Accrued expenses and other current liabilities

6,427

3,465

Taxes payable

11,792

1,609

Derivative liability

5,807

Current portion of convertible notes

1,652

Current portion of lease liability

1,909

972

Current portion of contingent consideration payable

2,393

750

Current portion of notes payable and accrued interest

3,372

6,190

Total current liabilities

38,074

18,852

Convertible notes

14,722

35,607

Notes payable and accrued interest from related party

45,362

44,289

Long term notes payable

1,907

1,903

Long term accounts payable

1,600

1,600

Contingent consideration payable

3,103

4,714

Deferred tax liability

7,670

Lease liability

51,545

20,976

TOTAL LIABILITIES

163,983

127,941

SHAREHOLDERS’ EQUITY

Equity attributable to 4Front Ventures Corp.

250,583

252,656

Additional paid-in capital

40,686

25,618

Deficit

(250,548)

(203,497)

Non-controlling interest

52

(17)

TOTAL SHAREHOLDERS’ EQUITY

40,773

74,760

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$

204,756

$

202,701

4Front Ventures Corp.
Formerly 4Front Holdings, LLC
Consolidated Statements of Operations and Comprehensive Loss
For the Years Ended December 31, 2020 and 2019

Amounts expressed in thousands of U.S. dollars except for share and per share data

December 31,

2020

December 31,

2019

REVENUE

Revenue from sale of goods

$

46,616

$

14,812

Real estate income

11,019

4,220

Total revenues

57,635

19,032

Cost of goods sold, sale of grown and manufactured products

(11,973)

(6,844)

Cost of goods gold, sale of purchased products

(9,151)

(4,007)

Gross profit

36,511

8,181

OPERATING EXPENSES

Selling and marketing expenses

23,174

9,038

General and administrative expenses

20,494

24,984

Depreciation and amortization

4,061

3,163

Equity based compensation

5,306

5,913

Impairment of goodwill and intangible assets

16,748

145,203

Foreign exchange (gain) loss

(19)

57

Accretion

(643)

(337)

Total operating expenses

69,121

188,021

Loss from operations

(32,610)

(179,840)

Other income (expense)

Interest income

77

85

Interest expense

(15,779)

(5,559)

Change in fair value of derivative liability

(1,578)

5,317

Gain on sale leaseback transactions

3,345

Gain on restructuring of notes payable

380

Gain on extinguishment of debt

1,218

Loss on investments

(759)

(529)

Other

763

2,500

Total other income (expense)

(12,333)

1,814

Net loss before income taxes

(44,943)

(178,026)

Income tax expense

(15,049)

(966)

Net loss from continuing operations

(59,992)

(178,992)

Net income (loss) from discontinued operations, net of taxes

12,987

(3,133)

Net loss

(47,005)

(182,125)

Net income (loss) attributable to non-controlling interest

46

(115)

Net loss attributable to shareholders

$

(47,051)

$

(182,010)

Basic and diluted loss per share

$

(0.09)

$

(0.43)

Weighted average number of shares outstanding, basic and diluted

520,563,800

420,306,991

Note Regarding Non-GAAP Measures, Reconciliation, and Discussion

In this press release, 4Front refers to certain non-GAAP financial measures such as Systemwide Pro Forma Revenue and Adjusted EBITDA. These measures do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other issuers. 4Front defines Systemwide Pro Forma Revenue as total revenue plus revenue from entities with which the Company has a management contract, or effectively similar relationship (net of any management fee or effectively similar revenue) but does not consolidate the financial results of per US GAAP ASC 810. 4Front considers this measure to be an appropriate indicator of the growth and scope of the business.

Adjusted EBITDA is defined by the Company as earnings before interest, taxes, depreciation and amortization less share-based compensation expense and one-time charges related to acquisition, financing related costs and other non-recurring expenses. 4Front considers these measures to be an important indicator of the financial strength and performance of our business.

This news release was prepared by management of 4Front Ventures, which takes full responsibility for its contents. The Canadian Securities Exchange (“CSE”) has not reviewed and does not accept responsibility for the adequacy of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States .

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in 4Front Ventures‘ periodic filings with securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of 4Front Ventures, statements regarding when or if transactions will close or if/when required conditions to closing are attained, the impact of the transactions on the business of 4Front and other statements regarding future developments of the business. Although 4Front Ventures has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on satisfying closing conditions, [obtaining regulatory approvals]; and engagement in activities currently considered illegal under U.S. federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. 4Front Ventures disclaims any intention or obligation to update or revise such information, except as required by applicable law, and 4Front Ventures does not assume any liability for disclosure relating to any other company mentioned herein.

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/4front-announces-fourth-quarter-and-fiscal-year-2020-results-and-provides-business-update-301263476.html

SOURCE 4Front

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/06/c1501.html

News Provided by Canada Newswire via QuoteMedia

(TheNewswire)

Keep reading... Show less

Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products

Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.

Keep reading... Show less

Further to its press release dated April 12, 2021, Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that it has oversubscribed and upsized its non-brokered private placement (the “Offering”) due to strong investor demand. The Company now anticipates that the Offering will be completed for gross proceeds of not less than $550,000.00, consisting of not less than 2,910,053 units (“Units”) at a price of $0.189 per Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one Common Share purchase warrant (a “Warrant”). Each Warrant is exercisable to acquire one Common Share at an exercise price of C$0.38 per Common Share for a period of 36 months from the date of closing of the Offering (the “Closing Date”), scheduled for April 22, 2021. The Units will have a hold period of four months and one day from the date of issuance.

Ayurcann CEO Igal Sudman commented: “We are very pleased with the demand we are seeing for the Offering. The feedback we have received to date is showing that our business is resonating with investors. We’re looking forward to closing the offering and proceeding with the planned Phase 2 build out, which will help greatly increase our facility’s capacity.”

Keep reading... Show less

UK InstaCoin APP Promises to Open NFTs up to the Masses through Social Media

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on its recent investment in InstaCoin Technologies Ltd., a newly formed UK entity

Keep reading... Show less

Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.

The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.

Keep reading... Show less